Valaciclovir placebo

DRUG2 trials

Sponsors

Assistance Publique Hopitaux De Paris, Heidelberg ImmunoTherapeutics GmbH

Conditions

Diseases [C] - Virus Diseases [C02]Herpes Genitalis

Phase 2

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection

CompletedNCT04165122

Heidelberg ImmunoTherapeutics GmbHHerpes Genitalis

Start: 2019-11-15End: 2021-11-01Updated: 2022-01-18

Phase 3

CYMEVALIII - Prenatal treatment of congenital cytomegalovirus infection with letermovir randomized against valaciclovir (CYMEVAL) III

Not yet recruitingCTIS2024-512869-14-00

Assistance Publique Hopitaux De ParisDiseases [C] - Virus Diseases [C02]

Target: 46Updated: 2024-07-22

Related Papers

Safety and efficacy of monoclonal antibody therapy in patients with chronic herpes simplex virus-2 genital infections: MATCH-2, a randomized double-blinded, parallel-group phase 2 multi-center trial.

2025-10-16